Kitasato Daiichi Sankyo Vaccine Co., Ltd.
Kitasato Daiichi Sankyo Vaccine Co., Ltd., a prominent player in the biopharmaceutical industry, is headquartered in Japan. Established in 2005, the company has rapidly evolved, focusing on the research, development, and production of innovative vaccines. With a strong operational presence in Asia and beyond, Kitasato Daiichi Sankyo is dedicated to addressing global health challenges through its advanced vaccine solutions.
The company’s core offerings include a range of vaccines designed to combat infectious diseases, distinguished by their cutting-edge technology and rigorous safety standards. Kitasato Daiichi Sankyo has achieved notable milestones, including collaborations with international health organisations, positioning itself as a trusted name in vaccine development. With a commitment to quality and innovation, the company continues to play a vital role in enhancing public health worldwide.
+24 vs industry average
Kitasato Daiichi Sankyo Vaccine Co., Ltd.’s score of 62 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Kitasato Daiichi Sankyo Vaccine Co., Ltd.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Kitasato Daiichi Sankyo Vaccine Co., Ltd. yet.
Kitasato Daiichi Sankyo Vaccine Co., Ltd.'s reported carbon emissions
Kitasato Daiichi Sankyo Vaccine Co., Ltd., headquartered in Japan, currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of Daiichi Sankyo Company, Limited, which may influence its climate commitments and initiatives.
While Kitasato Daiichi Sankyo Vaccine Co., Ltd. has not set specific reduction targets or disclosed its own climate pledges, it inherits sustainability initiatives from its parent company, Daiichi Sankyo Company, Limited. This includes participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which aim to enhance corporate accountability in reducing carbon emissions and transitioning to renewable energy sources.
As a subsidiary, Kitasato Daiichi Sankyo Vaccine Co., Ltd. aligns with the broader climate strategies of Daiichi Sankyo Company, Limited, which are designed to mitigate environmental impact and promote sustainability within the pharmaceutical and vaccine sectors.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Kitasato Daiichi Sankyo Vaccine Co., Ltd.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Kitasato Daiichi Sankyo Vaccine Co., Ltd. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Daiichi Sankyo Company, Limited
Carbon Disclosure Project
Inherited from Daiichi Sankyo Company, LimitedThe Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Inherited from Daiichi Sankyo Company, LimitedClimate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project